New drug cocktail aims to shrink Hard-to-Treat adrenal tumors

NCT ID NCT06006013

Recruiting now Disease control Sponsor: Emory University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase II trial is testing whether combining cabozantinib (a drug that blocks tumor growth and blood vessel formation) with pembrolizumab (an immunotherapy that helps the immune system attack cancer) can shrink tumors in people with advanced adrenocortical carcinoma. The study enrolls 21 adults whose cancer has spread, is locally advanced, or cannot be surgically removed. Participants receive both drugs and are monitored for tumor response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabozantinib and pembrolizumab
What this could lead to: If it works, this could point toward a new treatment option for advanced adrenal cancer that has spread or cannot be removed by surgery.
What could go wrong: This is a small, early-phase trial with only 21 participants, so results may not apply to everyone. The combination may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADRENAL CORTICAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenal carcinoma adrenal cortex carcinoma adrenal cortex neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADRENAL CORTICAL CARCINOMA LOCALLY ADVANCED ADRENAL CORTEX CARCINOMA STAGE III ADRENAL CORTEX CARCINOMA STAGE IV ADRENAL CORTEX CARCINOMA AJCC V8 UNRESECTABLE ADRENAL CORTEX CARCINOMA

Contacts and locations

Locations

Emory University Hospital Midtown
RECRUITING

Atlanta, Georgia, 30308, United States
Emory University Hospital/Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.